These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 4507613)

  • 1. Inactivator of the third component of complement as an inhibitor in the properdin pathway.
    Alper CA; Rosen FS; Lachmann PJ
    Proc Natl Acad Sci U S A; 1972 Oct; 69(10):2910-3. PubMed ID: 4507613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b).
    Gitlin JD; Rosen FS; Lachmann PJ
    J Exp Med; 1975 May; 141(5):1221-6. PubMed ID: 1168693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.
    Charlesworth JA; Williams DG; Sherington E; Lachmann PJ; Peters DK
    J Clin Invest; 1974 Jun; 53(6):1578-87. PubMed ID: 4830223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3.
    Alper CA; Bloch KJ; Rosen FS
    N Engl J Med; 1973 Mar; 288(12):601-6. PubMed ID: 4686987
    [No Abstract]   [Full Text] [Related]  

  • 5. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.
    Ziegler JB; Alper CA; Rosen RS; Lachmann PJ; Sherington L
    J Clin Invest; 1975 Mar; 55(3):668-72. PubMed ID: 1117072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum.
    Alper CA; Goodkofsky I; Lepow IH
    J Exp Med; 1973 Feb; 137(2):424-37. PubMed ID: 4734403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
    Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
    J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
    Tyson KR; Elkins C; de Silva AM
    J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A molecular concept of the properdin pathway.
    Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properdin: initiation of alternative complement pathway.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1975 Aug; 72(8):3220-4. PubMed ID: 1059108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of properdin in the alternate pathway of complement activation.
    Götze O; Müller-Eberhard HJ
    J Exp Med; 1974 Jan; 139(1):44-57. PubMed ID: 4808709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule.
    Day NK; Schreiber RD; Götze O; Müller-Eberhard HJ
    Scand J Immunol; 1976; 5(6-7):715-20. PubMed ID: 981969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
    Vogt W; Schmidt G; Dieminger L; Lynen R
    Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of properdin convertase and properdin in the alternative pathway of complement activation.
    Spitzer RE; Stitzel AE; Urmson J
    Immunochemistry; 1976 Jan; 13(1):15-20. PubMed ID: 943370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.